|
|
|
|
X4 Pharmaceuticals Inc (NASDAQ: XFOR) |
|
|
|
| |
X4 Pharmaceuticals Inc's Leverage Ratio
XFOR's quarterly Leverage Ratio and Total Liabilities, Equity growth
Due to repayements of liabilities of -12.99% X4 Pharmaceuticals Inc improved Leverage Ratio in first quarter 2025 to 4.67, below the company's average Leverage Ratio.
Within Biotechnology & Pharmaceuticals industry in the first quarter 2025, 70 other companies have achieved lower Leverage Ratio than X4 Pharmaceuticals Inc in the Q1 2025. While Leverage Ratio total ranking has improved so far in the first quarter 2025 to 1933, from total ranking in the fourth quarter 2024 at 3357 .
Explain Leverage Ratio?
How much Total Liabilitiess XFOR´s has?
|
Select the Comparisons :
|
|
Select the Ratio:
|
|
| XFOR Leverage Ratio |
(Mar 31 2025)
Q1 |
(Dec 31 2024)
Q4 |
(Sep 30 2024)
Q3 |
(Jun 30 2024)
Q2 |
(Mar 31 2024)
Q1 |
| Y / Y Equity Change |
2114.67 % |
-67.23 % |
-11.72 % |
82.78 % |
-98.6 % |
| Y / Y Total Liabilities Change |
-2.68 % |
17.65 % |
12.04 % |
60.7 % |
36.94 % |
| Leverage Ratio MRQ |
4.67 |
5.56 |
1.97 |
1.22 |
106.19 |
| XFOR's Total
Ranking |
# 1933 |
# 3357 |
# 2527 |
# 946 |
# 2918 |
| Seq. Equity Change |
3.59 % |
-62.85 % |
-36.88 % |
9016.89 % |
-98.47 % |
| Seq. Total Liabilities Change |
-12.99 % |
4.88 % |
2.03 % |
4.52 % |
5.19 % |
| Leverage Ratio first quarter 2025 Company Ranking |
| Within: |
No. |
| Biotechnology & Pharmaceuticals Industry |
# 71 |
| Healthcare Sector |
# 416 |
| Overall Market |
# 1933 |
| Leverage Ratio Statistics |
| High |
Average |
Low |
| 106.19 |
4.9 |
0.24 |
| (Mar 31 2024) |
|
(Dec 31 2019) |
Cumulative X4 Pharmaceuticals Inc's Leverage Ratio
XFOR's Leverage Ratio for the trailling 12 Months
XFOR Leverage Ratio |
(Mar 31 2025)
12 Months |
(Dec 31 2024)
12 Months |
(Sep 30 2024)
12 Months |
(Jun 30 2024)
12 Months |
(Mar 31 2024)
12 Months |
| Y / Y Equity TTM Growth |
6.03 % |
-32.05 % |
-12.7 % |
5.96 % |
-12.91 % |
| Y / Y Total Liabilities TTM Growth |
18.31 % |
28.84 % |
45.57 % |
72.28 % |
70.43 % |
| Leverage Ratio TTM |
2.32 |
2.63 |
2.01 |
1.88 |
2.08 |
| Total Ranking TTM |
# 18
| # 18
| # 13
| # 12
| # 13
|
| Seq. Equity TTM Growth |
12.36 % |
-20.41 % |
-3.43 % |
22.77 % |
-27.99 % |
| Seq. Total Liabilities TTM Growth |
-0.63 % |
4.13 % |
2.9 % |
11.11 % |
8.22 % |
On the trailing twelve months basis Due to repayements of liabilities of -12.99% X4 Pharmaceuticals Inc decreased Leverage Ratio in the 12 months ending in Q1 2025 to 2.32, above the X4 Pharmaceuticals Inc's average Leverage Ratio. Leverage Ratio is the average cumulative value over the last four quarters.
Among companies in the Biotechnology & Pharmaceuticals industry XFOR recorded the lowest Leverage Ratio. While total ranking remained unchanged compared to previous 12 month period at no. 18.
Explain Leverage Ratio?
How much Total Liabilitiess XFOR´s has?
| TTM Leverage Ratio Company Ranking |
| Within: |
No. |
| Within the Biotechnology & Pharmaceuticals Industry |
# 0 |
| Healthcare Sector |
# 0 |
| Within the Market |
# 18 |
| trailing twelve months Leverage Ratio Statistics |
| High |
Average |
Low |
| 2.65 |
1 |
0.31 | | (Dec 31 2024) |
|
(Jun 30 2020) |
|
Date modified: 2025-05-23T09:22:02+00:00
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
